The conversation around artificial intelligence in regulatory affairs has generated more confusion than clarity. On one side, there are enthusiastic claims about AI replacing regulatory writers, automating submission review, and transforming compliance operations. On the other hand, experienced regulatory professionals push back with well-founded scepticism. The practical reality sits between these positions but understanding precisely where AI is useful and where it is not requires more specificity than most industry commentary provides.
For regulatory teams evaluating AI investments in 2026, the most useful question is not “will AI change regulatory affairs?” It clearly will. The question is where it creates actual efficiency today, and where over-reliance on it introduces risk.
What AI Can Do Well in Regulatory Affairs Right Now
Current AI capabilities, particularly large language models and natural language processing tools trained on regulatory and biomedical content, are genuinely effective in several narrow, well-defined tasks.
- Literature review and evidence synthesis: AI tools can scan, filter, and summarise large volumes of published literature substantially faster than a human team. For periodic benefit-risk evaluation reports (PBRERs) and clinical overview preparation, this is a meaningful time-saving capability.
- Regulatory intelligence monitoring: AI-powered surveillance tools can track agency updates, guidance publications, and legislative changes across multiple jurisdictions simultaneously. For companies operating in ten or more markets, this reduces the risk of missed deadlines or regulatory surprises.
- Gap analysis against regulatory templates: Some AI tools are trained to compare draft documents against standard templates, ICH CTD modules, FDA guidance checklists, or EMA assessment report structures and flag missing sections or inconsistent terminology. This works reliably when the reference framework is well-defined.
- Translation and cross-referencing: AI accelerates the production of document cross-references, hyperlinking between CTD modules, and the adaptation of globally authored documents for local market submission requirements.
Where AI Consistently Falls Short
| Task | AI Performance | Why |
|---|---|---|
| Regulatory strategy formulation | Poor | Requires jurisdictional expertise and contextual judgement. |
| Risk-benefit assessment narratives | Unreliable | Nuanced clinical and regulatory reasoning cannot be automated. |
| Novel product pathway determination | Poor | Multi-agency coordination and precedent interpretation required. |
| Responding to agency questions | Not suitable | Demands regulatory relationship understanding and negotiation. |
| MedDRA coding for complex cases | Moderate risk | Coding errors require expert validation; liability remains with the MAH. |
The most dangerous application of AI in regulatory contexts is using it for tasks that appear straightforward but require regulatory judgement and then not validating the output rigorously. This is where teams lose time. An AI tool may produce a plausible-looking document section that contains factual errors, outdated guideline references, or logically inconsistent conclusions. Without subject-matter expert review, these errors pass through.
The Time Cost of Misapplied AI
Regulatory teams that implement AI tools without a clear validation and oversight framework often discover an unintuitive outcome: the tools create more work, not less. This happens because:
- AI-generated content requires thorough expert review before it can be submitted to any health authority.
- Teams must develop and maintain AI-specific SOPs and validation documentation for GxP-relevant processes.
- Training staff to use AI tools appropriately, including knowing when not to use them, takes time and resources that are not always budgeted.
The FDA has issued guidance indicating that AI-assisted tools used in regulatory submissions must be disclosed and validated appropriately, consistent with the principles of its AI/ML Action Plan. Companies that have not formalised their AI governance frameworks face increasing scrutiny on this point.
Practical Framework for AI in Regulatory Operations
Effective AI adoption in regulatory affairs requires a clear task classification:
- AI-led, human-reviewed: Literature triage, regulatory tracking, document cross-referencing.
- AI-assisted, human-authored: First drafts of standard sections (quality modules, SmPC formatting), translation review.
- Human-led, AI-unsupported: Regulatory strategy, agency interactions, risk-benefit assessment, pathway determination.
Teams that apply this classification rigorously will find that AI generates real efficiency in category one, measured gains in category two, and should not be in category three at all.
Conclusion
AI is neither the transformative revolution its proponents claim nor the irrelevance its critics suggest. In regulatory affairs, its value is real but bounded, and the boundaries matter enormously for compliance and submission quality. The teams that benefit most from AI are those with a clear-eyed assessment of what the tools can and cannot do, robust validation protocols, and experienced regulatory professionals who retain ownership of judgment-dependent decisions.
DDReg has integrated AI-supported tools into specific, validated workflows across regulatory intelligence, document gap analysis, and submission support with subject-matter expert oversight embedded at every stage. Our approach treats technology as an efficiency mechanism within an expert-led regulatory operation, not as a substitute for it.